187 related articles for article (PubMed ID: 37316640)
1. In deep bioinformatic characterization of a novel fumarate hydratase variant FH c.199T > G; (p.Tyr67Asp) in hereditary leiomyomatosis and renal cell carcinoma.
Chami A; de Souza Zózimo TR; Alves TM; Matosinho CGR; Santos C; Simões MM; Cabral WLR; de Paula Ricardo BF; da Silva Filho AL; Carvalho MRS; da Conceição Braga L
Fam Cancer; 2023 Oct; 22(4):481-486. PubMed ID: 37316640
[TBL] [Abstract][Full Text] [Related]
2. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
3. Segregation, immunohistochemical, molecular and functional analyses classify a novel missense variant in fumarate hydratase (FH) as pathogenic.
Ouchene L; Wilde B; Chan-Pak-Choon F; Camacho Valenzuela J; Brimo F; Witkowski L; Christofk H; Domecq C; Fu L; Weber E; Lemieux Anglin B; Netchiporouk E; Foulkes WD
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23221. PubMed ID: 38682608
[TBL] [Abstract][Full Text] [Related]
4. A Missense Mutation c.1132G > A in Fumarate Hydratase (FH) Leads to Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome and Insights into Clinical Management in Uterine Leiomyomata.
Shi Y; Xu Y; Wang C; Chen Y; Ren X; Kang Y; Wang C
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36981015
[TBL] [Abstract][Full Text] [Related]
5. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
[TBL] [Abstract][Full Text] [Related]
6. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
7. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
[TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
9. Cryptic splice mutation in the fumarate hydratase gene in patients with clinical manifestations of Hereditary Leiomyomatosis and Renal Cell Cancer.
Crooks DR; Cawthon GM; Fitzsimmons CM; Perez M; Ricketts CJ; Vocke CD; Yang Y; Middelton L; Nielsen D; Schmidt LS; Tandon M; Merino MJ; Ball MW; Meier JL; Batista PJ; Linehan WM
Hum Mol Genet; 2023 Nov; 32(22):3135-3145. PubMed ID: 37561409
[TBL] [Abstract][Full Text] [Related]
10. Prospective Detection of Germline Mutation of Fumarate Hydratase in Women With Uterine Smooth Muscle Tumors Using Pathology-based Screening to Trigger Genetic Counseling for Hereditary Leiomyomatosis Renal Cell Carcinoma Syndrome: A 5-Year Single Institutional Experience.
Rabban JT; Chan E; Mak J; Zaloudek C; Garg K
Am J Surg Pathol; 2019 May; 43(5):639-655. PubMed ID: 30741757
[TBL] [Abstract][Full Text] [Related]
11. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
12. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
13. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
14. Hereditary leiomyomatosis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: Bridging morphology and clinical screening.
Garg K; Rabban J
Genes Chromosomes Cancer; 2021 Mar; 60(3):210-216. PubMed ID: 33099845
[TBL] [Abstract][Full Text] [Related]
15. Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.
Lu E; Hatchell KE; Nielsen SM; Esplin ED; Ouyang K; Nykamp K; Zavoshi S; Li S; Zhang L; Wilde BR; Christofk HR; Boutros PC; Shuch B
Cancer; 2022 Feb; 128(4):675-684. PubMed ID: 34724198
[TBL] [Abstract][Full Text] [Related]
16. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
17. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma.
Zhang L; Walsh MF; Jairam S; Mandelker D; Zhong Y; Kemel Y; Chen YB; Musheyev D; Zehir A; Jayakumaran G; Brzostowski E; Birsoy O; Yang C; Li Y; Somar J; DeLair D; Pradhan N; Berger MF; Cadoo K; Carlo MI; Robson ME; Stadler ZK; Iacobuzio-Donahue CA; Joseph V; Offit K
Hum Mutat; 2020 Jan; 41(1):103-109. PubMed ID: 31444830
[TBL] [Abstract][Full Text] [Related]
18. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
19. Uterine leiomyomatosis in adolescents and young adults (AYAs) may represent a narrow phenotypic variant of FH tumour predisposition syndrome.
Foo T; Nama V; Attygalle AD; Williams J; Heelan K; Butler S; McVeigh TP
Fam Cancer; 2022 Jul; 21(3):357-362. PubMed ID: 34519924
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and molecular characteristics of fumarate hydratase-deficient uterine smooth muscle tumors: a single-center study of 52 cases.
Li H; Yang W; Tu X; Yu L; Huang D; Cheng Y; Chang B; Tang S; Ge H; Bao L; Zhou X; Bi R
Hum Pathol; 2022 Aug; 126():136-145. PubMed ID: 35659509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
